Evidence map›Paper›PMID 25418030›Full record

ReviewCytometry. Part A : the journal of the International Society for Analytical Cytology2015

Biology and flow cytometry of proangiogenic hematopoietic progenitors cells.

Jonathan A Rose, Serpil Erzurum, Kewal Asosingh

Abstract readReview
In one paragraph

Review in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Circulating angiogenic progenitor cell apoptosis in Post-COVID-19 syndrome.International journal of cardiology. Heart & vasculature · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Using the Autofluorescence Finder on the Sony ID7000Frontiers in bioengineering and biotechnology · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Fulvestrant for the Treatment of Pulmonary Arterial Hypertension.Annals of the American Thoracic Society · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jonathan A RoseDepartment of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.
Serpil Erzurum
Kewal Asosingh

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
Targeting pathological hyaluronan matricesP01HL103453 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI REIZES, OFER · 2011 to 2020
$26.8M
Tissue Processing and Cell Culture COreP01HL081064 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ARONICA, MARK A · 2006 to 2019
$17.8M
VIRALLY-INDUCED STAT-1, STAT-3 AND STAT-6M01RR018390 · NCRR · CLEVELAND CLINIC LERNER COM-CWRU · PI CULVER, DANIEL A · 2003 to 2007
$11.0M
Pulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1M
NITRIC OXIDE PRODUCTION AND REACTIONS IN THE LUNGR01HL060917 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Serpil C. Erzurum · 1999 to 2026
$6.3M
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*U10HL109250 · NHLBI · UNIVERSITY OF VIRGINIA · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2011 to 2016
$4.2M
Nitric Oxide in Pulmonary HypertensionR37HL060917 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2009 to 2018
$3.9M
Pulmonary Vascular-Right Ventricular Axis Research ProgramR01HL115008 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C., PRASAD, SATHYAMANGLA V · 2012 to 2016
$3.1M
NCI NIH HHS P30 CA043703NCRR NIH HHS M01 RR018390NHLBI NIH HHS P01 HL081064NHLBI NIH HHS P01 HL103453NHLBI NIH HHS R01 HL060917NHLBI NIH HHS R01 HL115008NHLBI NIH HHS R24 HL123767NHLBI NIH HHS R37 HL060917NHLBI NIH HHS U10 HL109250
6 · The paper itself

Abstract

During development, hematopoiesis and neovascularization are closely linked to each other via a common bipotent stem cell called the hemangioblast that gives rise to both hematopoietic cells and endothelial cells. In postnatal life, this functional connection between the vasculature and hematopoiesis is maintained by a subset of hematopoietic progenitor cells endowed with the capacity to differentiate into potent proangiogenic cells. These proangiogenic hematopoietic progenitors comprise a specific subset of bone marrow (BM)-derived cells that homes to sites of neovascularization and possess potent paracrine angiogenic activity. There is emerging evidence that this subpopulation of hematopoietic progenitors plays a critical role in vascular health and disease. Their angiogenic activity is distinct from putative "endothelial progenitor cells" that become structural cells of the endothelium by differentiation into endothelial cells. Proangiogenic hematopoietic progenitor cell research requires multidisciplinary expertise in flow cytometry, hematology, and vascular biology. This review provides a comprehensive overview of proangiogenic hematopoietic progenitor cell biology and flow cytometric methods to detect these cells in the peripheral blood circulation and BM.

Indexed as

Neovascularization, PhysiologicAntigens, CDBone MarrowCell DifferentiationCell LineageCytokinesEndothelial CellsEndothelium, VascularFlow CytometryGene ExpressionHemangioblastsHematopoiesisHumansReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AAntigens, CDCytokinesReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AVEGFA protein, humanangiogenesishematopoiesisproangiogenic cellsprogenitors

Identifiers

PMID25418030
PMCPMC4356492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.